UPDATE 2-US FDA panel backs Allos' lymphoma drug | Reuters
Links shared publicly online about this topic.
- 1,777total visits
UPDATE 2-US FDA panel backs Allos' lymphoma drug | Reuters
* FDA panel votes 10-4 in support of Folotyn * Panelists say conflicted but see benefit for some * Company says pleased with panel's support (Adds comments from meeting, company reaction, byline)
View full resource at reuters.com
Tags: Cancer, Lymphoma, Non-Hodgkin Lymphoma, Drug, FDA
Most Recently Shared on September 2, 2009 at 9:38 pm By:
FDA cmtee approves Folotyn for relapsed Peripheral T-Cell Lymphoma (PTCL) pts. today. http://bit.ly/eFtZU
UPDATE 2-US FDA staff question Allos lymphoma drug data | Reuters
reuters.com — “* FDA advisory panel to review drug Wednesday * Company says drug offers meaningful benefit * Shares fall over 6 percent (Recasts; adds FDA, analyst comment; updates shares) By Lisa Richwine WASHINGTON,” View full resource at reuters.com
Most Recently Shared on August 30, 2009 at 1:50 am By:
FDA questions data on Allos's new proposedT-cell drug Folotyn. http://bit.ly/kYzJh
Advertisement
